Heng Hu

Dr. Heng Hu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2011 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
XCXi Chen
Xi Chen
ZHZhibin Hu
Zhibin Hu
WWWenjing Wang
Wenjing Wang
YBYi Ba
Yi Ba
LMLijia Ma
Lijia Ma
CZChen-Yu Zhang
Chen-Yu Zhang
The detection of nonsmall cell lung cancer (NSCLC) at an early stage presents a daunting challenge due to the lack of a specific noninvasive marker. The discovery of microRNAs (miRNAs), particularly those found in serum, has opened a new avenue for tumor diagnosis. To determine whether the expression profile of serum miRNAs can serve as a NSCLC fingerprint, we performed Taqman probe‐based quantitative RT‐PCR assay to selected differentially expressed serum miRNAs from a sample set including 400 NSCLC cases and 220 controls, and risk score analysis to evaluate the diagnostic value of the serum miRNA profiling system. After a two‐phase selection and validation process, 10 miRNAs were found to have significantly different expression levels in NSCLC serum samples compared with the control serum samples. Risk score analysis showed that this panel of miRNAs was able to distinguish NSCLC cases from controls with high sensitivity and specificity. Under ROC curves, the AUC for tumor identification in training set and validation set were 0.966 and 0.972, respectively. Furthermore, the expression profile of the 10‐serum miRNAs was correlated with the stage of NSCLC patients, especially in younger patients and patients with current smoking habits. More importantly, the serum miRNA‐based biomarker for early NSCLC detection was supported by a retrospective analysis in which the 10‐serum miRNA profile could accurately classify serum samples collected up to 33 months ahead of the clinical NSCLC diagnosis. Taken together, we demonstrate that the profiling of 10‐serum miRNAs provides a novel noninvasive biomarker for NSCLC diagnosis.

5 December 2013 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
LCLong Chen
Long Chen
SZShuang Zhou
Shuang Zhou
JQJie Qin
Jie Qin
HHHeng Hu
Heng Hu
HMHuiying Ma
Huiying Ma
CLChunmin Liang
Chunmin Liang
Background: Secondary lymphoid tissue chemokine (SLC) is a key CC chemokine for chemotaxis of immune cells and has been an attractive candidate for anti-tumor treatments. However, among the immune cells recruited by SLC to tumors, the CD25+ Foxp3+ regulatory T cells (Tregs) compromise the anti-tumor effects. In this study, we proposed the combination therapy of intratumoral co-administration of SLC and anti-CD25 monoclonal antibodies (mAbs). We hypothesized that the intratumoral injections of SLC and depletion of Tregs would have stronger inhibition effects on the progression of hepatocellular carcinoma (HCC) in mice. Methods: C57BL/6 mice were inoculated subcutaneously with the murine HCC cell line, and mice with visible tumors were treated intratumorally with SLC, SLC plus anti-CD25 mAbs or the control antibodies. The percentages of Tregs, effector CD8+ T cells and CD4+ T cells were checked in the tumors, lymph nodes, spleen and liver at regular intervals. The levels of intratumoral IL-12, IFN-γ, IL-10 and TGF-β1 were evaluated. The final anti-tumor effects were measured by the tumor volume and weight as well as the intratumoral activity of MMP2 and MMP9. Bone-marrow-derived dendritic cells were used to explore the mechanisms of maturation induced by SLC in vitro. Results: Our experiments showed the combination therapy significantly decreased the frequency of Tregs, and increased CD8+ T cells and CD4+ T cells at tumor sites. These alterations were accompanied by an increased level of IL-12 and IFN-γ, and decreased level of IL-10 and TGF-β1. Unexpectedly, we observed a significantly decreased percentage of Tregs, and increased CD8+ T cells and CD4+ T cells in the lymph nodes, spleen and liver after the combination therapy. The growth and invasiveness of HCC was also maximally inhibited in the combination therapy compared with the SLC alone. Furthermore, we confirmed SLC induced the maturation of DCs via NF-κB p65 and this maturation would benefit the combination therapy. Conclusions: Our data demonstrated that intratumoral co-administration of SLC and anti-CD25 mAbs was an effective treatment for HCC, which was correlated with the altered tumor microenvironment and systemically optimized percentages of Tregs, CD8+ T cells and CD4+ T cells in peripheral immune organs.

7 July 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LCLong Chen
Long Chen
HMHuiying Ma
Huiying Ma
HHHeng Hu
Heng Hu
LGLingling Gao
Lingling Gao
XWXuan Wang
Xuan Wang
CLChunmin Liang
Chunmin Liang
Regulatory T cells (Tregs) exhibit functional abnormalities in the context of hepatocellular carcinoma (HCC). The microRNAs (miRNAs) are identified as the key modulators in Tregs. This study was to explore whether the expression profiles of miRNAs of Tregs were different in HCC-activated Tregs and whether Foxp3 had special effects on them.

27 May 2014 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
HMHuiying Ma
Huiying Ma
YWYe Wei
Ye Wei
YLYongmei Leng
Yongmei Leng
SLShichao Li
Shichao Li
LGLingling Gao
Lingling Gao
CLChunmin Liang
Chunmin Liang

26 February 2013 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MJMin Jiang
Min Jiang
GGGuohao Gu
Guohao Gu
BNBin Ni
Bin Ni
WWWenjing Wang
Wenjing Wang
JSJinfang Shi
Jinfang Shi
HHHeng Hu
Heng Hu

1 May 2015
Verified
Journal Article
Closed access
HHHeng Hu
Heng Hu
LGLingling Gao
Lingling Gao
CWCun Wang
Cun Wang
YLYan Li
Yan Li
HMHuiying Ma
Huiying Ma
CLChunmin Liang
Chunmin Liang